Study Shows Remdesivir, Gilead’s Fast-Tracked Coronavirus Treatment Drug, Fails To Mitigate Deaths

We will have to have this peer reviewed.

They will also need to try it earlier, to see if there is benefit there.

Like hydroxychloroquine. This MAY merely be a case of bad cohort selection.

.

Study Shows Remdesivir, Gilead’s Fast-Tracked Coronavirus Treatment Drug, Fails To Mitigate Deaths

OCTOBER 17, 2020 By Tristan Justice

A new study out Thursday shows remdesivir, the only antiviral therapeutic approved for treatment of the novel Wuhan coronavirus, does not prevent deaths in COVID-19-infected patients.

The study, conducted by the World Health Organization (WHO) tracked more than 11,300 adults across 30 different countries to examine the mortality rate benefits of the drug manufactured by Gilead. President Donald Trump was administered the medicine following symptoms related to his infection with the virus.

According to researchers in a paper that has not yet been peer-reviewed, remdesivir, hydroxychloroquine, lopinavir, and interferon drugs, when administered either separately or in a combination, “appeared to have little or no effect on hospitalized COVID-19, as indicated by overall mortality, initiation of ventilation and duration of hospital stay.”

Remdesivir was given emergency authorization by the Food and Drug Administration in May after a study from the National Institutes of Health found the drug produced modest benefits in coronavirus-stricken patients. The National Institutes of Health also includes seven doctors paid by the drug’s producer on its coronavirus panel. . . .

1 Like

I heard this too, this so-called promising drug is now looking like a flop. One would have to examine the data closely.

1 Like

The drug was never promised to do more than stop the replication of the virus. If the bodily damage is severe enough other treatments are needed.

1 Like
DISCLAIMER: The views and opinions expressed in these forums do not necessarily reflect those of Catholic Answers. For official apologetics resources please visit www.catholic.com.